Endpoints News
Biotech uses ‘digital twins’ in muscular dystrophy trial Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
26 June, 2026
Advising. Financing. Global Strategy.
Stay Current on Healthcare Equity Markets, M&A, and Venture Financing
sponsored by DNB Carnegie/Back Bay
spotlight
bioregnum
top stories
1. Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug
2. How one biotech is using 'digital twins' to study a muscle disease therapy
3. Lycia raises $75M for food allergy and Graves’ disease
4. After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
5.
peer review
Michael Gilman retires as Arrakis CEO; Daniel Skovronsky joins Illumina's board of directors
6. RTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investment strategy
more stories
 
Karen Weintraub
.

Earlier this month at ASCO, a lung cancer readout from Summit and Akeso was met with a tepid response, despite strong results and a plenary podium. Now, in an exclusive interview with Max Gelman, CEO Michelle Xia pushes back against the criticism of Akeso’s drug and research. 

.
Karen Weintraub
Deputy Editor, Endpoints News
Michelle Xia, Akeso CEO
1
by Max Gelman

Ake­so lead­er­ship is push­ing back on some of the ques­tions about its next-gen­er­a­tion can­cer drug raised ear­li­er this month at the an­nu­al Amer­i­can So­ci­ety of Clin­i­cal...

Read the full story
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
2
by Lei Lei Wu

Epi­crispr Biotech­nolo­gies on Fri­day shared an ear­ly cut of da­ta from its study of an epi­ge­net­ic edit­ing ther­a­py for a ge­net­ic dis­ease that leads to...

Read the full story
Lycia CEO Aetna Wun Trombley
3
by Kyle LaHucik

Bay Area biotech Ly­cia Ther­a­peu­tics is re­fu­el­ing with $75 mil­lion for its pro­tein degra­da­tion plat­form co-found­ed by No­bel lau­re­ate Car­olyn Bertozzi.

The com­pa­ny snagged the...

Read the full story
Endpoints webinars
Jul 30
1:00 pm ET
Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights
GUARDANT
4
by Kyle LaHucik

Bio­gen has paused or can­celed in­vest­ment in the “ma­jor­i­ty” of re­search pro­grams that came with its $5.6 bil­lion ac­qui­si­tion of Apel­lis Phar­ma­ceu­ti­cals and laid off...

Read the full story
Peer Review: Weekly biopharma job report